Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart failure nasal spray trial pulled before it began

NCT ID NCT07375212

Symptom relief Sponsor: Prisma Health-Upstate Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aimed to see if a single dose of bumetanide given as a nasal spray could quickly lower blood pressure in the lungs and reduce blood volume in people with heart failure. Participants would have had a heart monitor implanted. However, the trial was withdrawn before enrolling anyone, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bumetanide (intranasal)
What this could lead to
If it works, this could point toward a convenient, non-injectable way to manage fluid overload in heart failure patients at home.
What could go wrong
This trial was withdrawn before enrolling anyone, so no data exist. Even if run, it was a small pilot study with a single dose, so results would be very preliminary and may not lead to a practical treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Started

Jan 2026

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 y with chronic HF (NYHA II-III). * Successful CardioMEMS or Cordella implantation ≥ 3 months prior. * Clinically mild or worse congestion (no IV diuretics within 7 days). * eGFR ≥ 20 mL/min/1.73 m²; serum K⁺ 3.5-5.2 mmol/L. Exclusion Criteria: * SBP \< 90 mmHg, HR \< 50 bpm, or \> 110 bpm at baseline. * Acute HF hospitalization \< 30 days. * Chronic nasal pathology or recent intranasal surgery. * Known allergy to bumetanide or sulfamides. * Pregnancy or lactation. * Participation in the active treatment or follow-up phase of another clinical study of an investigational drug or device which has not reached its primary endpoint.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure, congestive are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

congestive heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure, congestive

Contacts and locations

Locations

  • Prisma Health

    Greenville, South Carolina, 29605, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.